{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T22:49:35Z","timestamp":1772578175617,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2003,11,25]],"date-time":"2003-11-25T00:00:00Z","timestamp":1069718400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2003,12]]},"DOI":"10.1038\/sj.bjc.6601437","type":"journal-article","created":{"date-parts":[[2003,11,25]],"date-time":"2003-11-25T20:37:00Z","timestamp":1069792620000},"page":"2031-2037","source":"Crossref","is-referenced-by-count":136,"title":["Bone resorption predicts for skeletal complications in metastatic bone disease"],"prefix":"10.1038","volume":"89","author":[{"given":"J E","family":"Brown","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C S","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S P","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S A","family":"Gutcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O P","family":"Purohit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R E","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2003,11,25]]},"reference":[{"key":"BF6601437_CR1","unstructured":"Ali SM, Demers LM, Leitzel K (2000) Elevated serum N-telopeptide predicts poor prognosis in breast cancer patients with bone metastases. Proc Am Soc Clin Oncol 19, Abstract 2549"},{"key":"BF6601437_CR2","volume-title":"Statistical Methods in Medical Research","author":"P Armitage","year":"1994","unstructured":"Armitage P, Berry G (1994) Statistical Methods in Medical Research, 3rd ed, Oxford: Blackwell Scientific Publications"},{"key":"BF6601437_CR3","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","volume":"91","author":"JR Berenson","year":"2001","unstructured":"Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W, Dreicer R, Kuross SA, Lipton A, Seaman JJ (2001) Zoledronic acid reduces skeletal events in patients with osteolytic metastases. Cancer 91: 1191\u20131200","journal-title":"Cancer"},{"key":"BF6601437_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/bjc.1987.13","volume":"55","author":"RE Coleman","year":"1987","unstructured":"Coleman RE, Rubens D (1987) The clinical course of bone metastases from breast cancer. Br J Cancer 55: 61\u201366","journal-title":"Br J Cancer"},{"key":"BF6601437_CR5","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1359\/jbmr.1997.12.4.624","volume":"12","author":"R Gonnelli","year":"1997","unstructured":"Gonnelli R, Cepollara C, Pondrelli C (1997) The usefulness of bone turnover in predicting the response to transdermal estrogen therapy in postmenopausal osteoporosis. J Bone Min Res 12: 624\u2013631","journal-title":"J Bone Min Res"},{"key":"BF6601437_CR6","first-page":"225","volume-title":"Bone Markers\u2013Biochemical and Clinical Perspectives","author":"DM Greenfield","year":"2000","unstructured":"Greenfield DM, Hannon RA, Eastell R (2000) The association between bone turnover and fracture risk (Sheffield Osteoporosis study). In Bone Markers\u2013Biochemical and Clinical Perspectives, Eastell R et al (eds) pp 225\u2013236, London: Martin Dunitz"},{"key":"BF6601437_CR7","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1002\/jbmr.5650071119","volume":"7","author":"DA Hanson","year":"1992","unstructured":"Hanson DA, Weis MA, Bollen AM (1992) Specific immunoassay for monitoring human bone resorption: quantitation of Type I collagen crosslinked N-telopeptides in urine. J Bone Min Res 7: 1251\u20131258","journal-title":"J Bone Min Res"},{"issue":"Suppl 11","key":"BF6601437_CR8","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0093-7754(01)90235-0","volume":"28","author":"BE Hillner","year":"2001","unstructured":"Hillner BE (2001) Pharmacoeconomic issues in bisphosphonate treatment of metastatic bone disease. Sem Oncol 28(Suppl 11): 64\u201368","journal-title":"Sem Oncol"},{"key":"BF6601437_CR9","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","volume":"335","author":"GN Hortobagyi","year":"1996","unstructured":"Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD (1996) Efficiency of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Eng J Med 335: 1785\u20131791","journal-title":"N Eng J Med"},{"key":"BF6601437_CR10","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1023\/A:1012506426440","volume":"12","author":"SP Jagdev","year":"2001","unstructured":"Jagdev SP, Purohit OP, Heatley S, Herling C, Coleman RE (2001) Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Ann Oncol 12: 1433\u20131438","journal-title":"Ann Oncol"},{"key":"BF6601437_CR11","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1016\/S0959-8049(98)00277-9","volume":"34","author":"A Lipton","year":"1998","unstructured":"Lipton A, Demers L, Curley E, Chinchilli V (1998) Markers of bone resorption in patients treated with pamidronate. Eur J Cancer 34: 2021\u20132026","journal-title":"Eur J Cancer"},{"key":"BF6601437_CR12","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1053\/ctrv.2000.0212","volume":"27","author":"A Lipton","year":"2001","unstructured":"Lipton A, Costa L, Ali SM, Demers LM (2001) Bone markers in the management of metastatic bone disease. Cancer Treatment Rev 27: 181\u2013185","journal-title":"Cancer Treatment Rev"},{"key":"BF6601437_CR13","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","volume":"88","author":"A Lipton","year":"2000","unstructured":"Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, Reitsma DJ, Heffernan M, Seaman JJ (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow up of two randomized, placebo controlled 'trials. Cancer 88: 1082\u20131090","journal-title":"Cancer"},{"issue":"Suppl 11","key":"BF6601437_CR14","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S0093-7754(01)90228-3","volume":"28","author":"P LoRusso","year":"2001","unstructured":"LoRusso P (2001) Analysis of skeletal related events in breast cancer and response to therapy. Sem Oncol 28(Suppl 11): 22\u201327","journal-title":"Sem Oncol"},{"key":"BF6601437_CR15","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1200\/JCO.2002.02.032","volume":"20","author":"HD Menssen","year":"2002","unstructured":"Menssen HD, Sakalova A, Fontana A, Herrmann Z, Boewer C, Facon T, Lichinitser MR, Singer CR, Euller-Ziegler L, Wetterwald M, Fiere D, Hrubisko M, Thiel E, Delmas PD (2002) Effects of long term intravenous ibandronate therapy on skeletal- related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol 20: 2353\u20132359","journal-title":"J Clin Oncol"},{"key":"BF6601437_CR16","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/bjc.1993.157","volume":"67","author":"MA Richards","year":"1993","unstructured":"Richards MA, Braysher S, Gregory WM, Rubens RD (1993) Advanced breast cancer: use of resources and cost implications. Br J Cancer 67: 856\u2013860","journal-title":"Br J Cancer"},{"issue":"Suppl 21","key":"BF6601437_CR17","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1053\/sonc.2002.37416","volume":"29","author":"L Rosen","year":"2002","unstructured":"Rosen L (2002) Efficacy and safety of Zoledronic acid in the treatment of bone metastases associated with lung cancer and other solid tumours. Sem Oncol 29(Suppl 21): 28\u201332","journal-title":"Sem Oncol"},{"key":"BF6601437_CR18","first-page":"33","volume-title":"Cancer and the Skeleton","author":"RD Rubens","year":"2000","unstructured":"Rubens RD (2000) Bone metastases-incidence and complications. In Cancer and the Skeleton, Rubens RD and Mundy GR (eds) 33\u201342. London: Martin Dunitz"},{"issue":"19","key":"BF6601437_CR19","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","volume":"94","author":"F Saad","year":"2002","unstructured":"Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B (2002) A randomised placebo-controlled trial of Zoledronic acid in patients with hormone refractory metastatic Prostate carcinoma. J Natl Cancer Inst 94(19): 1458\u20131468","journal-title":"J Natl Cancer Inst"},{"key":"BF6601437_CR20","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1200\/JCO.1999.17.3.846","volume":"17","author":"RL Theriault","year":"1999","unstructured":"Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF, Costello S, Kennedy I, Simeone J, Seamann JJ, Knight RD, Mellars K, Heffernan M, Reitsma DJ (1999) Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomised, placebo controlled trial. J Clin Oncol 17: 846\u2013854","journal-title":"J Clin Oncol"},{"key":"BF6601437_CR21","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/bjc.1996.210","volume":"73","author":"JJ Vinholes","year":"1996","unstructured":"Vinholes JJ, Gueo C-Y, Purohit OP, Eastell R, Coleman RE (1996) Metabolic effects of pamidronate in patients with metastatic bone disease. Br J Cancer 73: 1089\u20131095","journal-title":"Br J Cancer"},{"key":"BF6601437_CR22","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1023\/A:1008238422151","volume":"8","author":"JJ Vinholes","year":"1997","unstructured":"Vinholes JJ, Purohit OP, Abbey ME, Eastell R, Coleman RE (1997) Relationships between biochemical and symptomatic response in a double blind randomised trial of pamidronate for metastatic bone disease. Ann Oncol 8: 1243\u20131250","journal-title":"Ann Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6601437.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6601437","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6601437.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:54:19Z","timestamp":1684414459000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6601437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,11,25]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2003,12]]}},"alternative-id":["BF6601437"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6601437","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,11,25]]}}}